Biocept Inc (OTCPK:BIOCQ)

$ 0.0002 0 (0%) Market Cap: 1,000.00 Enterprise Value: 4.96 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Biocept Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Q3 2022 Biocept Inc Earnings Call Transcript
Nov 28, 2022

$23 (-3.46%)

Earnings
Q1 2022 Biocept Inc Earnings Call Transcript
Jun 07, 2022

$47.1 (+9.03%)

Earnings
Q3 2021 Biocept Inc Earnings Call Transcript
Nov 15, 2021

$119.7 (+1.01%)

Earnings
Q2 2021 Biocept Inc Earnings Call Transcript
Aug 16, 2021

$113.7 (-5.25%)

Earnings
Biocept Inc Reports Liquid Biopsy Highly Accurate In Detecting HER2 Protein In Breast Cancer Patients Transcript
Dec 21, 2020
Q3 2020 Biocept Inc Earnings Call Transcript
Nov 12, 2020

$184.8 (+24.95%)

Earnings
Biocept Inc Announces Highmark Makes A Positive Coverage Determination on Target Selector Liquid Biopsy Transcript
Sep 23, 2020
Q2 2020 Biocept Inc Earnings Call Transcript
Aug 12, 2020

$306 (+2.00%)

Earnings
Q1 2020 Biocept Inc Earnings Call Transcript
May 13, 2020

$131.64 (-0.27%)

Earnings
Q4 2019 Biocept Inc Earnings Call Transcript
Mar 25, 2020

$105 (+12.43%)

Earnings

Biocept Inc Reports Liquid Biopsy Highly Accurate In Detecting HER2 Protein In Breast Cancer Patients Transcript

Dec 21, 2020 / NTS GMT

Release Date Price: $148.5 (+0.61%)

Transcript

Christine Corrado

Proactive - Moderator

Hello, and thanks so much for watching Proactive New York. I'm Christine Corrado. Joining me right now is Mike Nall, CEO at Biocept. Mike, good to see you, how are you?

Mike Nall

Biocept, Inc. - President & CEO

Good, Christine.

Questions & Answers

Christine Corrado

Proactive - Moderator

Great to hear, Mike. Today, we're talking about how the group had results back from prospective study showing that its target selector at liquid biopsy was highly accurate in monitoring the HER2 protein. I mean, can you maybe explain first off why it's so important to be able to recognize the HER2 protein?

Mike Nall

Biocept, Inc. - President & CEO

Yeah. No, absolutely. So HER2 is a standard of care test in tissue for patients diagnosed with [breast cancer]. And in fact, it's one of the first, what we call biomarkers that was discovered and had a therapy associated with it called Herceptin. And a lot of investors have heard about

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.